Study
Phase
N
Experimental arm
Control arm OS HR OS Exp OS CON OS ab. diff PFS HR PFS Exp PFS CON PFS ab. diff
Subgroup: Chinese
NR
9.7
7.6
2.1
NR
7.2
4.7
2.5
GOLD (2016) [
35
]
III
525 Olaparib
+^
Paclitaxel
Paclitaxel
0.79
8.8
6.9
1.9
0.84
3.7
3.2
0.5
Subgroup: ATM-ve
0.73
12.0
10.0
2
0.74
5.3
3.7
1.6
REGARD (2014) [
25
]
III
355 Ramucirumab
Placebo
0.78
5.2
3.8
1.4
0.48
2.1
1.3
0.8
GRANITE-1 (2013) [
32
] III
656 Everolimus
Placebo
0.90
5.4
4.3
1.1
0.66
1.7
1.4
0.3
APATINIB (2016) [
27
]
III
267 Apatinib
Placebo
0.71
6.5
4.7
1.8
0.44
2.6
1.8
0.8
ONO4538 (2017) [
53
]
III
493 Nivolumab
Placebo
0.63
5.3
4.1
1.2
0.60
1.6
1.5
0.1
Abbreviations:
N
number of patients,
CON
control,
OS
overall survival (in months),
HR
hazard ratio,
OS (Exp)
overall survival in the experimental arm,
OS (ab. diff.)
absolute differ
ence of overall survival in two study arms (experimental
−
control),
PFS
progression-free survival,
PFS (Exp)
progression-free survival (in months) the experimental arm,
PFS (ab. diff.)
absolute difference of progression-free survival in two study arms (experimental
−
control),
PF
cisplatin
+
5FU,
PX
cisplatin
+ capecitabine,
IHC
immunohistochemistry,
FISH
flores-
cence in situ hybridization,
CAPOX
capecitabine
+
oxaliplatin,
EOC
epirubicin
+
oxaliplatin
+^
capecitabine,
ECX
epirubicin
+
cisplatin
+
capecitabine
Table 1(continued)